Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 453

1.

Disagreement between acute and chronic haemodynamic effects of nadolol in cirrhosis: a pathophysiological interpretation.

Merkel C, Bolognesi M, Sacerdoti D, Bombonato G, Cavasin L, Gatta A.

Aliment Pharmacol Ther. 2005 Sep 1;22(5):433-9.

2.

Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the beta-blocker alone.

Merkel C, Sacerdoti D, Bolognesi M, Enzo E, Marin R, Bombonato G, Angeli P, Gatta A.

Hepatology. 1997 Jul;26(1):34-9.

PMID:
9214449
3.
4.

Primary prophylaxis with nadolol in cirrhotic patients: Doppler patterns of splanchnic hemodynamics in good and poor responders.

Berzigotti A, Rinaldi MF, Magalotti D, Morelli MC, Zappoli P, Andreone P, Rossi C, Zoli M.

J Hepatol. 2006 Feb;44(2):310-6. Epub 2005 Nov 14.

PMID:
16343679
5.
6.

Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding.

Villanueva C, Aracil C, Colomo A, Hernández-Gea V, López-Balaguer JM, Alvarez-Urturi C, Torras X, Balanzó J, Guarner C.

Gastroenterology. 2009 Jul;137(1):119-28. doi: 10.1053/j.gastro.2009.03.048. Epub 2009 Apr 1.

PMID:
19344721
7.

Noninvasive hemodynamic measurements of superior mesenteric artery in the prediction of portal pressure response to propranolol.

Iwao T, Oho K, Sakai T, Sato M, Nakano R, Yamayaki M, Toyonaga A, Tanikawa K.

J Hepatol. 1998 May;28(5):847-55.

PMID:
9625321
8.

Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis.

Villanueva C, López-Balaguer JM, Aracil C, Kolle L, González B, Miñana J, Soriano G, Guarner C, Balanzó J.

J Hepatol. 2004 May;40(5):757-65.

PMID:
15094222
9.

The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis.

Merkel C, Bolognesi M, Sacerdoti D, Bombonato G, Bellini B, Bighin R, Gatta A.

Hepatology. 2000 Nov;32(5):930-4.

PMID:
11050041
10.

[Propranolol and 5-isosorbide mononitrate in patients with cirrhosis: systemic and portal hemodynamic events].

Castaño G, Viudez P, Sookoian S, Carlevaro O, Riccitelli M, Frider B.

Gastroenterol Hepatol. 2000 Jun-Jul;23(6):275-81. Spanish.

PMID:
15324622
11.

Effect of nadolol on liver haemodynamics and function in patients with cirrhosis.

Merkel C, Sacerdoti D, Finucci GF, Zuin R, Bazzerla G, Bolognesi M, Gatta A.

Br J Clin Pharmacol. 1986 Jun;21(6):713-9.

12.

Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis.

Narahara Y, Kanazawa H, Taki Y, Kimura Y, Atsukawa M, Katakura T, Kidokoro H, Harimoto H, Fukuda T, Matsushita Y, Nakatsuka K, Sakamoto C.

J Gastroenterol Hepatol. 2009 Nov;24(11):1791-7. doi: 10.1111/j.1440-1746.2009.05873.x. Epub 2009 Aug 3.

PMID:
19686420
13.

The acute and chronic effects of isosorbide-5-mononitrate on portal haemodynamics in cirrhosis.

Grose RD, Plevris JN, Redhead DN, Bouchier IA, Hayes PC.

J Hepatol. 1994 Apr;20(4):542-7.

PMID:
8051395
14.
15.

Comparison of Doppler ultrasonography and the hepatic venous pressure gradient in assessing portal hypertension in liver cirrhosis.

Choi YJ, Baik SK, Park DH, Kim MY, Kim HS, Lee DK, Kwon SO, Kim YJ, Park JW.

J Gastroenterol Hepatol. 2003 Apr;18(4):424-9.

PMID:
12653891
16.

Long-term haemodynamic effects of isosorbide 5-mononitrate in patients with cirrhosis and portal hypertension.

García-Pagán JC, Feu F, Navasa M, Bru C, Ruiz del Arbol L, Bosch J, Rodés J.

J Hepatol. 1990 Sep;11(2):189-95.

PMID:
2123914
17.

Effect of chronic treatment with nadolol plus isosorbide mononitrate on liver blood flow and liver metabolic activity in cirrhosis.

Merkel C, Sacerdoti D, Bolognesi M, Buonamico P, Sticca A, Amodio P, Angeli P, Micotti L, Gatta A.

Eur J Gastroenterol Hepatol. 1999 Nov;11(11):1221-5.

PMID:
10563530
18.

Clinical vs haemodynamic response to drugs in portal hypertension.

McCormick PA, Patch D, Greenslade L, Chin J, McIntyre N, Burroughs AK.

J Hepatol. 1998 Jun;28(6):1015-9.

PMID:
9672178
19.

Long-term effects of beta-adrenergic blockade with nadolol on hepatic and renal haemodynamics and function in cirrhotics.

Gatta A, Bolognesi M, Merkel C, Finucci GF, Angeli P, Sacerdoti D, Ruol A.

Clin Physiol. 1987 Oct;7(5):377-87.

PMID:
3665396
20.

Effects of nadolol treatment on renal and hepatic hemodynamics and function in cirrhotic patients with portal hypertension.

Gatta A, Sacerdoti D, Merkel C, Milani L, Battaglia G, Zuin R.

Am Heart J. 1984 Oct;108(4 Pt 2):1167-72.

PMID:
6148880
Items per page

Supplemental Content

Write to the Help Desk